Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Free Cash Flow (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Free Cash Flow for 4 consecutive years, with -$6.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 68.78% to -$6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$33.3 million, a 40.45% increase, with the full-year FY2025 number at -$33.3 million, up 40.45% from a year prior.
  • Free Cash Flow was -$6.5 million for Q4 2025 at Spruce Biosciences, up from -$48.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $12.7 million in Q1 2025 to a low of -$48.5 million in Q3 2025.
  • A 4-year average of -$10.3 million and a median of -$11.2 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 657.25% in 2024, then soared 184.9% in 2025.
  • Spruce Biosciences' Free Cash Flow stood at -$11.7 million in 2022, then grew by 4.51% to -$11.2 million in 2023, then plummeted by 84.47% to -$20.7 million in 2024, then surged by 68.78% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Free Cash Flow are -$6.5 million (Q4 2025), -$48.5 million (Q3 2025), and $8.9 million (Q2 2025).